1. Home
  2. LSBK vs ACET Comparison

LSBK vs ACET Comparison

Compare LSBK & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LSBK

Lake Shore Bancorp Inc.

HOLD

Current Price

$15.82

Market Cap

125.6M

Sector

Finance

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$8.78

Market Cap

77.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LSBK
ACET
Founded
1891
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
125.6M
77.3M
IPO Year
2025
2017

Fundamental Metrics

Financial Performance
Metric
LSBK
ACET
Price
$15.82
$8.78
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$48.33
AVG Volume (30 Days)
12.6K
98.7K
Earning Date
04-22-2026
05-06-2026
Dividend Yield
2.27%
N/A
EPS Growth
49.23
N/A
EPS
0.26
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$59.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.50
$0.46
52 Week High
$16.28
$9.47

Technical Indicators

Market Signals
Indicator
LSBK
ACET
Relative Strength Index (RSI) 48.72 58.89
Support Level $15.50 $7.36
Resistance Level $16.28 N/A
Average True Range (ATR) 0.17 0.58
MACD -0.03 0.09
Stochastic Oscillator 42.22 73.84

Price Performance

Historical Comparison
LSBK
ACET

About LSBK Lake Shore Bancorp Inc.

Lake Shore Bancorp Inc operates as a savings and loan holding company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit, and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: